Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73γ in lung cancer

FEBS Journal

Volumn 277, Issue 14, 2010, Pages 3014-3027

  Logotheti, Stella ^a   Michalopoulos, Ioannis ^b   Sideridou, Maria ^d   Daskalos, Alexandros ^d   Kossida, Sophia ^b   Spandidos, Demetrios A ^e   Field, John K ^d   Vojtesek, Borek ^f   Liloglou, Triantafyllos ^d   Gorgoulis, Vassilis ^c   Zoumpourlis, Vassilis ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF CRETE   (Greece)

^f MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Np73; lung cancer; P1 promoter; p73 isoforms; Sp1; TAp73

Indexed keywords

ISOPROTEIN; PROTEIN P73; PROTEIN TAP73; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

AGED; ARTICLE; BINDING ASSAY; BINDING SITE; BIOINFORMATICS; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; RNA INTERFERENCE; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; CONSERVED SEQUENCE; DNA; DNA-BINDING PROTEINS; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; OLIGODEOXYRIBONUCLEOTIDES; PLICAMYCIN; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN ISOFORMS; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954352759     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07710.x     Document Type: Article

References (49)

1. Minna JD, Roth JA Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1, 49 52.
2. Tokuchi Y, Hashimoto T, Kobayashi Y, Hayashi M, Nishida K, Hayashi S, Imai K, Nakachi K, Ishikawa Y, Nakagawa K et al. (1999) The expression of p73 is increased in lung cancer, independent of p53 alteration. Br J Cancer 80, 1623 1629.
3. Melino G, Lu X, Gasco M, Crook T Knight RA (2003) Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28, 663 670.
4. De Laurenzi V Melino G (2000) Evolution of functions within the p53/p63/p73 family. Ann NY Acad Sci 926, 90 100.
5. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C Vousden KH (2004) p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279, 8076 8083.
6. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi T Takahashi T (1998) Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58, 1380 1383.
7. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A et al. (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99 103.
8. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809 819.
9. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M Melino G (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188, 1763 1768.
10. De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A, Levrero M Knight RA (1999) Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 6, 389 390.
11. Ueda Y, Hijikata M, Takagi S, Chiba T Shimotohno K (1999) New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18, 4993 4998.
12. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T Ikawa S (2002) Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 62, 636 641.
13. Grob TJ, Novak U, Maisse C, Barcaroli D, Lüthi AU, Pirnia F, Hügli B, Graber HU, De Laurenzi V, Fey MF et al. (2001) Human δNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8, 1213 1223. (Pubitemid 34048476)
14. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH Putzer BM (2004) Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 10, 626 633.
15. Marabese M, Vikhanskaya F Broggini M (2007) p73: a chiaroscuro gene in cancer. Eur J Cancer 43, 1361 1372.
16. Tuve S, Wagner SN, Schittek B Putzer BM (2004) Alterations of DeltaTA-p73 splice transcripts during melanoma development and progression. Int J Cancer 108, 162 166.
17. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K Yasumoto K (2004) Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10, 6905 6911.
18. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI Liu W (1998) Activation of p73 silent allele in lung cancer. Cancer Res 58, 2347 2349.
19. Di Vinci A, Sessa F, Casciano I, Banelli B, Franzi F, Brigati C, Allemanni G, Russo P, Dominioni L Romani M (2009) Different intracellular compartmentalization of TA and δNp73 in non-small cell lung cancer. Int J Oncol 34, 449 456.
20. Nyman U, Sobczak-Pluta A, Vlachos P, Perlmann T, Zhivotovsky B Joseph B (2005) Full-length p73alpha represses drug-induced apoptosis in small cell lung carcinoma cells. J Biol Chem 280, 34159 34169.
21. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W et al. (2005) TAp73/DNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12, 1564 1577.
22. Seelan RS, Irwin M, van der Stoop P, Qian C, Kaelin WG Liu W (2002) The human p73 promoter: characterization and identification of functional E2F binding sites. Neoplasia 4, 195 203.
23. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH et al. (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407, 645 648.
24. Stiewe T Pützer BM (2001) Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26, 464 469.
25. Ding Y, Inoue T, Kamiyama J, Tamura Y, Ohtani-Fujita N, Igata E Sakai T (1999) Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. DNA Res 6, 347 351.
26. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC Xie K (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61, 4143 4154.
27. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao J Xie K (2007) Molecular basis of the synergistic antioncogenic activity of bevacizumab and mithramycin A. Cancer Res 67, 4878 4885.
28. Safe S Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41, 2438 2448.
29. Koutsodontis G, Vasilaki E, Chou WC, Papakosta P Kardassis D (2005) Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J 389, 443 455.
30. Buhlmann S, Racek T, Schwarz A, Schaefer S Pützer BM (2008) Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis. J Mol Biol 378, 20 30.
31. Beitzinger M, Oswald C, Beinoraviciute-Kellner R Stiewe T (2006) Regulation of telomerase activity by the p53 family member p73. Oncogene 25, 813 826.
32. Racek T, Mise N, Li Z, Stoll A Pützer BM (2005) C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J Biol Chem 280, 40402 40405.
33. Salimath B, Marmé D Finkenzeller G (2000) Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 19, 3470 3476.
34. Innocente SA Lee JM (2005) p73 is a p53-independent, Sp1-dependent repressor of cyclin B1 transcription. Biochem Biophys Res Commun 329, 713 718.
35. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H Inoue M (2000) Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 6, 1239 1247.
36. Xu D, Wang Q, Gruber A, Björkholm M, Chen Z, Zaid A, Selivanova G, Peterson C, Wiman KG Pisa P (2000) Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19, 5123 5133.
37. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS et al. (2008) TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22, 2677 2691.
38. Sauer M, Bretz AC, Beinoraviciute-Kellner R, Beitzinger M, Burek C, Rosenwald A, Harms GS Stiewe T (2008) C-terminal diversity within the p53 family members account for differences in DNA binding and transcriptional activity. Nucleic Acids Res 36, 1900 1912.
39. Takada N, Ozaki T, Ichimiya S, Todo S Nakagawara A (1999) Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. Cancer Res 59, 2810 2814.
40. Ozaki T, Naka M, Takada N, Tada M, Sakiyama S Nakagawara A (1999) Deletion of the COOH-terminal region of p73α enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res 59, 5902 5907.
41. Nyman U, Vlachos P, Cascante A, Hermanson O, Zhivotovsky B Joseph B (2009) Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain. Mol Cell Biol 29, 1814 1825.
42. Liontos M, Niforou K, Velimezi G, Vougas K, Evangelou K, Apostolopoulou K, Vrtel R, Damalas A, Kontovazenitis P, Kotsinas A et al. (2009) Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol 175, 376 391.
43. Halazonetis TD, Gorgoulis VG Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319, 1352 1355.
44. Hooghe B, Hulpiau P, van Roy F De Bleser P (2008) ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res 36, W128 W132.
45. Hubbard TJ, Aken BL, Ayling S, Ballester B, Beal K, Bragin E, Brent S, Chen Y, Clapham P, Clarke L et al. (2009) Ensembl 2009. Nucleic Acids Res 37, D690 D697.
46. Waterhouse AM, Procter JB, Martin DM, Clamp M Barton GJ (2009) Jalview Version 2 - a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189 1191.
47. Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41, 95 98.
48. Park YG, Nesterova M, Agrawal S Cho-Chung YS (1999) Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. J Biol Chem 274, 1573 1580.
49. Sayan AE, Paradisi A, Vojtesek B, Knight RA, Melino G Candi E (2005) New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun 330, 186 193.